BioHarvest Sciences (NASDAQ:BHST) Shares Down 1.1% – Here’s What Happened

Shares of BioHarvest Sciences Inc. (NASDAQ:BHST) were down 1.1% during trading on Thursday . The stock traded as low as $4.65 and last traded at $4.65. Approximately 18,552 shares were traded during trading, a decline of 51% from the average daily volume of 37,636 shares. The stock had previously closed at $4.70.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Wall Street Zen upgraded shares of BioHarvest Sciences to a “hold” rating in a research report on Saturday, October 18th. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $14.50.

BioHarvest Sciences Trading Down 1.1%

The company’s 50-day moving average is $5.38 and its 200 day moving average is $7.63. The company has a current ratio of 1.35, a quick ratio of 1.02 and a debt-to-equity ratio of 0.30. The firm has a market cap of $76.35 million, a PE ratio of -6.84 and a beta of 1.12.

BioHarvest Sciences (NASDAQ:BHST) last announced its earnings results on Thursday, November 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). The company had revenue of $9.07 million for the quarter, compared to the consensus estimate of $9.11 million. BioHarvest Sciences had a negative net margin of 36.33% and a negative return on equity of 1,041.86%. As a group, sell-side analysts predict that BioHarvest Sciences Inc. will post -0.8 EPS for the current year.

Hedge Funds Weigh In On BioHarvest Sciences

An institutional investor recently raised its position in BioHarvest Sciences stock. True North Advisors LLC lifted its stake in BioHarvest Sciences Inc. (NASDAQ:BHST) by 676.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 168,013 shares of the company’s stock after purchasing an additional 146,365 shares during the quarter. True North Advisors LLC owned 1.02% of BioHarvest Sciences worth $1,581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.